Translational Development Acquisition CORP 8-K filings

Translational Development Acquisition Corp. (TDAC) has entered into a definitive subscription agreement with Naetas Holding Limited for $50 million in Class A ordinary shares and warrants, a key step towards its business combination with ProLogium.

Translational Development Acquisition Corp. (TDAC) announced ProLogium's filing of a Registration Statement on Form F-4 with the SEC, advancing their de-SPAC transaction.

Translational Development Acquisition Corp. has amended its governing documents to extend the deadline for consummating a business combination up to June 24, 2027, with monthly extensions requiring sponsor deposits.

Translational Development Acquisition Corp. announced the conversion of 4,657,499 Class B ordinary shares into Class A ordinary shares held by its sponsor.

ProLogium, a solid-state battery developer, announced a business combination with Translational Development Acquisition Corp. (TDAC) to list on Nasdaq under the ticker PRLG.

Translational Development Acquisition Corp. secured a non-interest bearing promissory note for up to $2 million from its sponsor, TDAC Partners LLC, for working capital.

Translational Development Acquisition Corp. (TDACU) announced the commencement of separate trading for its Class A ordinary shares (TDAC) and warrants (TDACW) on the Nasdaq Global Market, following its initial public offering.

Translational Development Acquisition Corp. completed its initial public offering, raising $172.5 million and placing $174.225 million in trust for a future business combination.

Translational Development Acquisition Corp. successfully closed its initial public offering, raising $172.5 million, which included the full exercise of the underwriters' over-allotment option.